Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 19:9:503.
doi: 10.3389/fnins.2015.00503. eCollection 2015.

Evaluation of Models of Parkinson's Disease

Shail A Jagmag  1 , Naveen Tripathi  1 , Sunil D Shukla  2 , Sankar Maiti  1 , Sukant Khurana  1
Affiliations
Review

Evaluation of Models of Parkinson's Disease

Shail A Jagmag et al. Front Neurosci. .

Abstract

Parkinson's disease is one of the most common neurodegenerative diseases. Animal models have contributed a large part to our understanding and therapeutics developed for treatment of PD. There are several more exhaustive reviews of literature that provide the initiated insights into the specific models; however a novel synthesis of the basic advantages and disadvantages of different models is much needed. Here we compare both neurotoxin based and genetic models while suggesting some novel avenues in PD modeling. We also highlight the problems faced and promises of all the mammalian models with the hope of providing a framework for comparison of various systems.

Keywords: Parkinson's Disease; Parkinsonian Disorders; genetic models; lewy bodies; neurodegeneration; substantia nigra pars compacta (SNc); toxin models; ventral tegmental area (VTA).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of major toxin models. (A) 6-OHDA, (B) MPTP, (C) Rotenone, (D) Paraquat, (E) Methamphetamine. MAO A, Monoamine oxidase A; MAO B, Monamine Oxidase B; DAT, Dopaminergic Transporter; NAT, Noradrenergic Transporter; SNc, Substantia Nigra pars Compacta; VTA, Ventral tegmental area; VMAT2, Vesicular Monoamine Transporter 2.
See this image and copyright information in PMC

Comment in

  • Commentary: Evaluation of Models of Parkinson's Disease.
    Leal PC, Lins LC, de Gois AM, Marchioro M, Santos JR. Leal PC, et al. Front Neurosci. 2016 Jun 21;10:283. doi: 10.3389/fnins.2016.00283. eCollection 2016. Front Neurosci. 2016. PMID: 27444376 Free PMC article. No abstract available.

References

    1. Anand V. S., Braithwaite S. P. (2009). LRRK2 in Parkinson's disease: biochemical functions. FEBS J. 276, 6428–6435. 10.1111/j.1742-4658.2009.07341.x - DOI - PubMed
    1. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T. M., Thomas B., et al. . (2007). DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U.S.A. 104, 14807–14812. 10.1073/pnas.0703219104 - DOI - PMC - PubMed
    1. Anichtchik O., Diekmann H., Fleming A., Roach A., Goldsmith P., Rubinsztein D. C. (2008). Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J. Neurosci. 28, 8199–8207. 10.1523/JNEUROSCI.0979-08.2008 - DOI - PMC - PubMed
    1. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu I., Shah B., et al. . (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811–813. 10.1002/mds.25421 - DOI - PubMed
    1. Auluck P. K., Chan H. Y. E., Trojanowski J. Q., Lee V. M. Y., Bonini N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865–868. 10.1126/science.1067389 - DOI - PubMed